- $43.83m
- $59.04m
- 13
- 12
- 77
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 29.96 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -157.73% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 35.1 | 33.87 | 40.02 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
JanOne Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing novel, no-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or Peripheral Artery Disease (PAD) and treats pain. The Company’s drug candidate is a treatment for Peripheral Artery Disease, a condition that can cause severe pain and affects over 8.5 million people in the United States. The Company operates through the Biotechnology segment, which is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.
Directors
- Last Annual
- December 30th, 2023
- Last Interim
- December 30th, 2023
- Incorporated
- March 12th, 2018
- Public Since
- February 22nd, 2006
- No. of Shareholders
- 50
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 8,593,636
- Address
- 325 E Warm Springs Rd Ste 102, LAS VEGAS, 89119-4240
- Web
- https://janone.com/
- Phone
- +1 7029975968
- Auditors
- /s/ Hudgens CPA,PLLC
Upcoming Events for JAN
Q2 2024 Janone Inc Earnings Release
Janone Inc Annual Shareholders Meeting
Similar to JAN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Janone share price?
As of Today at 19:11 UTC, shares in Janone are trading at $5.10. This share price information is delayed by 15 minutes.
How has the Janone share price performed this year?
Shares in Janone last closed at $5.10 and the price had moved by +443.71% over the past 365 days. In terms of relative price strength the Janone share price has outperformed the S&P500 Index by +344.51% over the past year.
What are the analyst and broker recommendations for Janone?
There is no consensus recommendation for this security.
What is the Janone dividend yield?
Janone does not currently pay a dividend.
Does Janone pay a dividend?
Janone does not currently pay a dividend.
When does Janone next pay dividends?
Janone does not currently pay a dividend.
How do I buy Janone shares?
To buy shares in Janone you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Janone?
As of the previous close price of $5.10, shares in Janone had a market capitalisation of $43.83m.
Where are Janone shares listed?
Here are the trading details for Janone:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: JAN
What kind of share is Janone?
Based on an overall assessment of its quality, value and momentum Janone is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Janone share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Janone share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Janone. Over the past six months, its share price has outperformed the S&P500 Index by +1165.37%.
As of the last closing price of $5.10, shares in Janone were trading +376.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Janone PE Ratio?
The Janone PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Janone?
We do not have data on Janone's directors